MicroRNA Market

Global MicroRNA Market Size

The size of the global microRNA market was worth USD 1.61 billion in 2024. The global market is anticipated to grow at a CAGR of 20.12% from 2025 to 2033 and be worth USD 8.38 billion by 2033 from USD 1.93 billion in 2025.

MARKET DRIVERS

The growing use of MicroRNA as a biomarker is one of the major factors propelling the MicroRNA market growth. These biomarkers are essential for genome-wide population studies and data-driven methods due to their superior robustness and reproducibility in comparison to conventional procedures. Consequently, these molecules are promising candidates for the development of biomarkers. In addition, the importance of liquid biopsies in the discovery and development of biomarkers has increased as their popularity has increased.

The growing number of R&D activities to explore the potential of microRNA biomarkers further boost the market’s growth rate. Soon, a surge in research into the potential of MicroRNA biomarkers in prognosis, diagnosis, and therapeutics is anticipated to stimulate market growth. In January 2020, for instance, researchers used next-generation sequencing to investigate the viability of MicroRNA found in peripheral blood as a diagnostic biomarker for Bipolar II disorder (BD-II). MicroRNA s could serve as a non-invasive diagnostic tool for other neurodegenerative diseases.

Technological innovations further propel the growth rate of the MicroRNA market. Increasing the sensitivity and selectivity of microRNA detection through technological innovation contributes to the growth of the microRNA market. Nanoparticle-based amplification, RCA-based, DSN-based, LAMP-based, and enzyme-free amplification are among the newly developed techniques for microRNA detection. Similarly, in January 2020, scientists developed a program-based isothermal amplification technique for precise and quantitative digital measurement of MicroRNA. The system can reduce contamination because it is based on signal amplification as opposed to direct replication of the targeted sequence, as with PCR-based methods.

MARKET RESTRAINTS

The high costs associated with microRNAs majorly hamper the market growth. MicroRNAs have been discovered to be expensive, necessitating investment in microRNA science and other practices. Aside from that, microRNAs are a new technology, with several pieces already folded. The shortage of skilled professionals further hinders the market’s growth rate.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Services Insights

Based on services, the profiling, localization, and quantification services segment held the leading share of the global microRNA market in 2024 and is expected to grow at a healthy CAGR during the forecast period. The growing number of strategic collaborations between companies in the field of microRNA profiling services is majorly driving segmental expansion. The 3D Gene platform for microRNA profiling has enhanced performance and robustness for sample preparation, microRNA profiling, and data analysis workflow management.

Owing to a growing emphasis on the development of new microRNA purification methods, the isolation and purification segment is anticipated to grow at the fastest CAGR over the forecast period. Researchers developed a relatively new magnetic bead-based RNA purification method that incorporates specific RNA isolation kits for efficient analysis of small RNAs such as MicroRNA s. In addition, the RNA extracted using this method was suitable for mRNA and microRNA expression analysis using real-time polymerase chain reaction.

By Application Insights

Based on the application, the cancer segment accounted for the major share of the global market in 2024 and is predicted to register a healthy CAGR during the forecast period owing to the growing incidence of cancer, the significance of cancer cases in disease pathology, and concerning innovations in the role of microRNAs in cancer diagnosis via cancer-associated genomic regions. Several tumor suppressor microRNAs are typically inhibited during the translation of microRNAs that encode for oncogenes, thereby inhibiting tumor formation and cancer progression. Thus, microRNA dysregulation is well understood as a potential therapeutic target for a variety of cancer types.

Owing to the introduction of new molecular biomarkers for the early detection of cardiovascular diseases, the cardiovascular disease segment is anticipated to grow at a lucrative CAGR over the forecast period. Due to their tissue-specific expression patterns, stability, and secretion of the corresponding body fluids, microRNAs are attractive therapeutic targets for cardiovascular diseases. In addition, several studies have implicated microRNA in cardiovascular diseases.

By End-Users Insights

Based on end-user, the academic and government research institutes segment dominated the microRNA market in 2024. The growing number of initiatives from several governments to encourage academic and research institutions for the R&D around genomics propel the segmental growth. The growing significance of microRNA in the diagnosis of cancer, cardiovascular diseases and infectious diseases by diagnostic labs, CROs, and hospitals further contributes to the segment’s growth rate.

On the other hand, the biotechnology and pharmaceutical companies segment is predicted to account for a considerable share of the global market during the forecast period. Companies such as Regulus Therapeutics, Mirna Therapeutics, and miRagen Therapeutics invest heavily in the development of RNA-based therapeutics.

REGIONAL ANALYSIS

North America held the major share of the global microRNA market in 2024 and is predicted to hold the largest share of the global market throughout the forecast period. The strong presence of pharmaceutical and biotechnology companies, the availability of advanced healthcare infrastructure and increasing investments for R&D majorly drive the North American market growth. The favorable regulatory environment, high adoption rate of advanced technologies and the presence of major market players and collaborations between academic institutions and industry further contribute to the growth rate of the North American market.

Europe is another promising regional market for microRNA. It is predicted to register a healthy CAGR during the forecast period due to factors such as the presence of a well-established healthcare system, high prevalence of chronic diseases and growing demand for innovative diagnostic and therapeutic solutions like microRNA-based products. A strong focus on research and development, with several academic and research institutions actively involved in microRNA studies is another major factor propelling the European market growth. The presence of government initiatives and funding programs supporting genomics research and strategic collaborations between industry players and academic institutions have facilitated the development and commercialization of microRNA-based products in Europe. These factors further fuel the growth rate of the European market.

APAC is predicted to register the fastest CAGR during the forecast period owing to factors such as the presence of a large patient population, increasing healthcare expenditure, rising awareness about personalized medicine and advancements in healthcare infrastructure. The presence of a rapidly expanding biotechnology and pharmaceutical sector, favorable government initiatives and increasing collaborations between regional and international players further fuel the growth rate of the APAC market. The rising prevalence of chronic diseases and the need for effective diagnostic and therapeutic solutions is another key factor supporting regional market growth. China, Japan and India held the major share of the global market in 2024.

Regions such as Latin America and MEA held a moderate share of the global market in 2024.

KEY MARKET PARTICIPANTS

Merck KGaA., Illumina, Inc., Agilent Technologies, Thermo Fisher Scientific, Inc., System Biosciences LLC, Promega Corporation, Miltenyi Biotec, Rosetta Genomics Ltd., HTG Molecular Diagnostics, Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd, Qiagen N.V, Bioline GmbH (A Meridian Life Science Company), BioGenex, Horizon Discovery Ltd., GeneCopoeia, Inc, NanoString Technologies, Inc, BioDynamics Laboratory Inc. are some of the major players in the global microRNA market.

MARKET SEGMENTATION

This research report on the global microRNA market has been segmented and sub-segmented into the following categories.

By Product

• Instruments
  • By Technology
    • Real-Time PCR
    • Microarray
    • NGS
    • Others
  • By Workflow
    • Isolation & Purification
    • Whole Blood
    • Serum
    • Plasma
    • FFPE
    • Fresh Frozen Tissue
    • Others
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis & Others
  • Others
• Consumables
  • By Specimen
    • Whole Blood
    • Serum
    • Plasma
    • FFPE
    • Fresh Frozen Tissue
    • Others
  • By Workflow
    • Isolation & Purification
    • miRNA cDNA Synthesis
    • Profiling, Localization, & Quantification
    • Functional Analysis
    • Others

By Services

• Service Type
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis
    • Real-Time PCR
    • Microarray
    • NGS
    • Others
  • Others
• By Specimen
  • Whole Blood
  • Serum
  • Plasma
  • FFPE
  • Fresh Frozen Tissue
  • Others

By Application

• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others

By End-Users

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Other end-users

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa